Mitsubishi Tanabe's Internal Hemorrhoid Drug Launches In South Korea
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma announced June 10 that its internal hemorrhoid sclerotherapy agent Zione, which was jointly developed with Naha, Okinawa-based new drug development company Leqio Pharma, was launched in the South Korean market by Yuhan Corp, a Seoul-based Korean pharmaceutical company. (Click here for more - Japanese language ) "South Korean Pharmaceutical Company launched Internal Hemorrhoid Drug Developed By Mitsubishi Tanabe" - Jiji Press News (6/10/08)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.